Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Mexico lifts regulation requiring AIDS drug companies to have manufacturing plants in Mexico in order to sell generics

On the day of the opening ceremonies of the XVII International AIDS Conference in Mexico City, President Felipe Calderon announced his plans to lift a Mexican Ministry of Economy requirement that pharmaceutical companies operating in Mexico must have a manufacturing plant in that country in order to use or sell generic versions of their lifesaving AIDS and other drugs in Mexico.

4 Aug 2008

Barr confirms Xyzal tablet patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a challenge of the patent listed by UCB Inc. in connection with its Xyzal(R) Tablets (levocetirizine dihydrochloride), 5mg.

31 Jul 2008

A counter to counterfeit drugs

The counterfeiting of medicines has been known of since around 1990 and is a growing problem-in both developing and developed countries. Counterfeit medicines are estimated as more than 10% of the global medicines market and in some developing countries it is thought to be as high as 50%. One prediction is that global counterfeit drug sales will reach $75 billion by 2010.

30 Jul 2008

Barr confirms patent challenge of Sensipar tablets

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Amgen Inc. in connection with its Sensipar Tablets (cincalcet hydrochloride), 30mg, 60mg and 90mg.

29 Jul 2008

FDA approves first generic divalproex sodium for the treatment of seizures, bipolar disorder and migraine headaches

The U.S. Food and Drug Administration today approved the first generic versions of Depakote delayed-release tablets (divalproex sodium). Depakote is approved by the FDA for the treatment of seizures, bipolar disorder and migraine headaches.

29 Jul 2008

Barr confirms Fentora tablet patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Cephalon, Inc. in connection with its Fentora(R) Tablets (fentanyl citrate buccal tablets), equivalent to fentanyl base 100 mcg, 400 mcg, 600 mcg and 800 mcg.

24 Jul 2008

CMS proposal would limit industry practice that raises costs for some Medicare drug plan beneficiaries

A CMS proposal under consideration would limit a practice used by pharmacy benefit managers known as "lock-in pricing" that can increase costs for beneficiaries enrolled in the Medicare drug benefit and bring them into the so-called "doughnut hole" coverage gap more quickly, the Wall Street Journal reports.

23 Jul 2008

Patent for Aciphex ruled valid and enforceable

PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Federal Circuit Court of Appeals affirmed the judgments of the United States District Court for the Southern District of New York that the patent for Aciphex (rabeprazole sodium 20 mg tablets) is valid and enforceable.

21 Jul 2008

Teva Pharmaceutical Industries to buy Barr Pharmaceuticals

Teva Pharmaceutical Industries Ltd and Barr Pharmaceuticals, Inc. announced today that they have signed a definitive agreement under which Teva will acquire Barr, the fourth largest generic drug company worldwide.

18 Jul 2008

Wyeth and Impax settle Effexor XR patent case

Wyeth and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's Effexor XR antidepressant have been approved by the United States District Court for the District of Delaware.

17 Jul 2008

FDA makes changes to drug approval process

The U.S. Food and Drug Administration has announced that it is revising the way it communicates to drug companies when a marketing application cannot be approved as submitted.

9 Jul 2008

Nanomaterials key to new strategies for blocking metastasis

A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.

9 Jul 2008

Black box warning for epilepsy drugs

The U.S. Food and Drug Administration (FDA) is calling for the strongest type of warning to be placed on drugs which are used to treat epilepsy.

8 Jul 2008

Brazilian organization files opposition to Gilead's antiretroviral patent application in India

The Brazilian group Interdisciplinary AIDS Association, or ABIA, has joined Indian patient advocacy groups to oppose a patent application for Gilead Science's antiretroviral drug Tenofovir, saying that the patent would have a direct impact on Brazil's ability to produce and access affordable generic versions of the drug, India's Business Standard reports. Opponents of the patent say that the drug consists of a previously known compound and, therefore, cannot be patented under India's Patents Act.

2 Jul 2008

FDA approves generic Risperidone for the treatment of schizophrenia, bipolar disorder

The U.S. Food and Drug Administration today approved the first generic versions of Risperdal (risperidone) tablets. Risperdal is an antipsychotic drug used for the treatment of schizophrenia, bipolar disorder, and other psychiatric conditions.

1 Jul 2008

Scientists challenge the public to predict the best way to control disease epidemics

Scientists will be challenging the public this week to pit their powers of prediction against the latest computer simulations. A brand new interactive exhibit will be displayed at the Royal Society's summer science exhibition that showcases the value of mathematical models in the fight to prevent and control diseases such as bluetongue.

30 Jun 2008

Watson Pharmaceuticals launches generic version of dronabinol

Watson Pharmaceuticals, Inc. has announced that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths.

30 Jun 2008

Barr announces favorable ruling in Mirapex patent challenge

Barr Pharmaceuticals, Inc. has announced that U.S. District Court for Delaware has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Boehringer Ingelheim Pharmaceuticals, Inc. in connection with Boehringer Ingelheim's Mirapex(R) Tablets (pramipexole dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

26 Jun 2008

Report finds 32% increase in drug industry lobbying spending in 2007

The pharmaceutical industry spent $168 million on lobbying in 2007, a 32% increase over the previous year, according to a report released Tuesday by the Center for Public Integrity, the Wall Street Journal reports.